Symbicort Onset of Action 1
Study Details
Study Description
Brief Summary
The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 budesonide/formoterol |
Drug: budesonide/formoterol (Symbicort)
Other Names:
|
Active Comparator: 2 fluticasone/salmeterol |
Drug: fluticasone/salmeterol (Advair Diskus)
Other Names:
|
Active Comparator: 3 albuterol |
Drug: albuterol (Ventolin)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- FEV1 3 minutes post dose [4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)]
Secondary Outcome Measures
- 12 hour serial FEV1 [4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)]
- Patients perception of effect [4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of asthma and baseline lung function test results as determined by protocol
-
Required and received asthma maintenance therapy within previous 4 weeks at doses determined by protocol
Exclusion Criteria:
-
Severe asthma or asthma markedly affected by seasonal factors
-
Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AstraZeneca
Investigators
- Study Director: Catherine Bonuccelli, AstraZeneca
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SD-039-0732
- D5896C00732